Skip to main content

Table 3 Tumor response (n = 35)

From: Phase II clinical trial assessing the addition of hyperthermia to salvage concurrent chemoradiotherapy for unresectable recurrent head and neck cancer in previously irradiated patients

Complete response (CR)

19 (54.3%)

Partial response (PR)

10 (28.6%)

Stable disease (SD)

4 (11.4%)

Progressive disease (PD)

2 (5.7%)

Overall response rate (CR + PR), %

82.9%

Disease control rate (CR + PR + SD), %

94.3%

  1. Values are number (percentage) unless otherwise noted
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us